New drug trial offers hope for Hard-to-Treat kidney diseases
NCT ID NCT05732402
Summary
This study is testing a new drug called povetacicept in adults with several autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The main goals are to see if the drug is safe and if it helps control these diseases. Participants receive the drug by injection every four weeks for at least six months, with options to continue longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site (102)
Nedlands, Western Australia, 6009, Australia
-
Investigational Site (116)
Suwon, Gyeonggi-do, 16499, South Korea
-
Investigational Site (118)
Colleyville, Texas, 76034, United States
-
Investigational Site (125)
Seoul, Gyeonggi-do, 03080, South Korea
-
Investigational Site (191)
Caguas, 00725, Puerto Rico
-
Investigational Site (501)
Phoenix, Arizona, 85302, United States
-
Investigational Site (502)
Lawrenceville, Georgia, 30046, United States
-
Investigational Site (503)
Boston, Massachusetts, 02115, United States
-
Investigational Site (504)
Goyang-si, Gyeonggi-do, 10444, South Korea
-
Investigational Site (505)
Anyang-si, Gyeonggi-do, 14068, South Korea
-
Investigational Site (506)
Valencia, California, 91335, United States
-
Investigational Site (507)
Cheonan, Chungcheongnam-do, 31151, South Korea
-
Investigational Site (508)
Brooklyn, New York, 11203, United States
-
Investigational Site (509)
Newark, New Jersey, 07103, United States
-
Investigational Site (510)
Guri-si, Gyeonggi-do, 11923, South Korea
-
Investigational Site (511)
Albany, New York, 12209, United States
-
Investigational Site (512)
Orlando, Florida, 32806, United States
-
Investigational Site (513)
Arvada, Colorado, 80002, United States
-
Investigational Site (515)
Saint Albans, Victoria, 3021, Australia
-
Investigational Site (516)
Houston, Texas, 77054, United States
-
Investigational Site (518)
Bethlehem, Pennsylvania, 18017, United States
-
Investigational Site (519)
Concord, New South Wales, 2139, Australia
-
Investigational Site (520)
Seoul, Gyeonggi-do, 03181, South Korea
-
Investigational Site (521)
Seoul, Gyeonggi-do, 05278, South Korea
-
Investigational Site (523)
Phoenix, Arizona, 85016, United States
-
Investigational Site (524)
Tucson, Arizona, 85712, United States
-
Investigational Site (525)
Tamarac, Florida, 33321, United States
-
Investigational Site (526)
Irving, Texas, 75061, United States
-
The Johns Hopkins University School of Medicine
Baltimore, Maryland, 21224, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.